Valuation: Nektar Therapeutics

Market Cap 2.29B 2B 1.89B 1.71B 3.21B 220B 3.22B 22.6B 8.72B 112B 8.61B 8.42B 360B P/E 2026 *
-8.2x
P/E 2027 * -6.37x
Enterprise Value 2.2B 1.92B 1.81B 1.65B 3.09B 211B 3.1B 21.73B 8.38B 107B 8.28B 8.09B 346B EV / Sales 2026 *
52.6x
EV / Sales 2027 * 36.5x
Free-Float
99.65%
Yield 2026 *
-
Yield 2027 * -
1 day-1.84%
1 week-3.81%
Current month-6.00%
1 month-8.88%
3 months+10.04%
6 months-8.31%
Current year+58.70%
1 week 65.75
Extreme 65.75
70
1 month 65.75
Extreme 65.75
77.76
Current year 33.4
Extreme 33.4
109
1 year 33.4
Extreme 33.4
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
290.55
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 A Sell

Chief Executive Officer

-418 0.0012%
8/18/26 A Sell

Chief Technology Officer

-186 0.0006%
7/24/26 A Free

Chief Technology Officer

16,500 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
-1.84%-3.81%+14.19%+553.04% 2.29B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.71%+1.10%+34.91%+243.34% 27.71B
Weighted average by Cap. -0.48%+1.40%+36.32%+151.32%

Financials

2026 *2027 *
Net sales 41.88M 36.52M 34.48M 31.31M 58.66M 4.02B 58.91M 413M 159M 2.04B 157M 154M 6.57B 57M 49.7M 46.93M 42.62M 79.84M 5.47B 80.18M 562M 217M 2.78B 214M 209M 8.95B
Net income -249M -217M -205M -186M -348M -23.86B -350M -2.45B -946M -12.13B -934M -913M -39.03B -367M -320M -302M -274M -514M -35.22B -516M -3.62B -1.4B -17.91B -1.38B -1.35B -57.62B
Net Debt -88.02M -76.75M -72.47M -65.81M -123M -8.45B -124M -868M -335M -4.29B -331M -323M -13.82B -210M -183M -173M -157M -295M -20.19B -296M -2.07B -801M -10.26B -790M -773M -33.02B
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
18/09/26 $67.10 -1.84% 2,806,733
17/09/26 $68.36 +1.45% 1,264,866
16/09/26 $67.38 +1.11% 986,116
15/09/26 $66.64 -2.72% 1,257,783
14/09/26 $68.50 -1.81% 920,047
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
67.10USD
Average target price
144.40USD
Spread / Average Target
+115.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!